Sign up United Kingdom
Proactive Investors - Run By Investors For Investors

ValiRx has raised £1.15mln via a share placing to accelerate its clinical and pre-clinical portfolio

The AIM-listed firm said it issued 76,666,666 new ordinary shares at a price of 1.50p each in the placing undertaken by the company's broker, Novum Securities
Cancer cells
ValiRx said the net proceeds will be used to extend and expand the scope of the clinical trial of VAL201 to treat prostate cancer

ValiRx PLC (LON:VAL), the clinical stage biotechnology company, has raised £1.15mln via a placing to accelerate its clinical and pre-clinical portfolio, welcoming new investors in the process.

The AIM-listed firm said it issued 76,666,666 new ordinary shares at a price of 1.50p each in the placing undertaken by the company's broker, Novum Securities.

WATCH: Commercial discussions for ValiRx's lead cancer drug progressing 'rapidly'

The group said the net proceeds of the placing will be used to extend and expand the scope of the clinical trial of VAL201 to treat prostate cancer and to thereby allow the treatment to more speedily reach its full therapeutic potential and potential anti-cancer impact. 

It added that the funds will also be used to progress the development of the pre-clinical VAL301 and VAL101 programmes and towards clinical trials.

Dr Satu Vainikka, ValiRx’s CEO commented: "I am grateful for the support we have received from both new and existing investors and their investment will enable the Company to further progress and accelerate its clinical and pre-clinical portfolio, namely VAL101, 201 and 301 and move these therapeutic assets closer to their respective value inflection points".

View full VAL profile View Profile

ValiRx Plc Timeline

Related Articles

man and woman working in a lab
October 11 2018
There were no adverse safety findings and excellent drug-like properties were confirmed.
Dog skeleton with cannabis plant leaf
July 17 2018
The company's lead drug candidate is a cannabis-derived canine pain medication.
A paper plane about to be launched with the help of surgical scissors
Tue
The voluntarily-suspended company is progressing an ongoing recapitalisation plan.

© Proactive Investors 2018

Proactive Investors Limited, trading as “Proactiveinvestors United Kingdom”, is Authorised and regulated by the Financial Conduct Authority.
Registered in England with Company Registration number 05639690. Group VAT registration number 872070825 FCA Registration number 559082. You can contact us here.

Market Indices, Commodities and Regulatory News Headlines copyright © Morningstar. Data delayed 15 minutes unless otherwise indicated. Terms of use